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T lymphocytes first carried foreign genes safely into humans over two decades ago.
Since these pioneering studies, scientific techniques to better understand the genomic
landscape of cells has directly led to a more sophisticated appreciation of the diversity,
functional complexity, and therapeutic potential ofT cells.Through the use of mouse mod-
els, we now know the function of the many genes that are critical for T cells to recognize
foreign, mutated, or self-antigens and the factors responsible for the lineage diversifica-
tion of T cells that lead to inhibitory or stimulatory immune responses. This knowledge
combined with well-established modalities to introduce genes into T cells allows for the
design of effector and memory CD8 and CD4 T lymphocytes specific for viral, fungal,
bacterial, parasitic, and tumor-antigens and to design regulatory lymphocytes specific for
the self-antigens responsible for autoimmune and inflammatory diseases. Here, I review
strategies for designing the idealT cell by introducing genes controlling (1) the secretion of
cytokines/chemokines and their receptors, (2)T-cell receptor specificity, (3) chimeric-antigen
receptors that enable for the recognition of surface antigens in an MHC-independent fash-
ion, (4) co-stimulatory/inhibitory surface molecules, and (5) disease defining single-gene
factors.
Keywords: gene therapy, cancer, immunotherapy, T cells, inflammation, chimeric-antigen receptors, cytokines,
severe combined immunodeficiency
INTRODUCTION
The Deoxyribonucleic acid (DNA) molecule, perhaps one of biol-
ogy’s greatest discoveries, helped unlock the secrets to the flow
of genetic information that we now know forms the basis for the
complexity of all life on earth. In the 1960s, the scientific commu-
nity demonstrated for the first time that exogenous DNA could be
taken up and ectopically expressed in mammalian cell lines (1).
Shortly after, a growing understanding of viral reverse transcrip-
tion processes and advances in recombinant DNA technologies
paved the way for engineering viruses to carry therapeutic genes
into cells (2).
Fast-forward 40 years and there now exists numerous viral and
non-viral modalities to introduce therapeutic genes into cells. The
most common viral vectors include retroviruses, adenovirus, and
herpes simplex viral backbones with non-viral modalities cen-
tered on physical (DNA transfection/electroporation) or chemical
(synthetic oligonucleotides, lipoplexes, nanoparticles) methods of
delivery and transposon systems (3–6). Of these various modal-
ities, gene therapy using retroviral based vectors is perhaps the
most established methodology both in experimental models and
in human clinical trials due to the ability to stably integrate genes
into dividing cells (7–9).
In addition to the technologic advancements in gene therapy, a
growing understanding of the genetic causes of human disease and
the downstream function and network-like interactions between
specific genes are enabling scientists to devise strategies to treat
ailments once thought incurable (10, 11). While the in vivo deliv-
ery of genes targeting specific cell types remains a grand hope
for the future, current methodologies readily enable for the stable
introduction of foreign genes into cells ex vivo, allowing for the
transfer of these cells back into patients (6).
T lymphocytes represent the ideal vehicle for carrying ther-
apeutic genes into humans. T cells are easily obtained through
peripheral blood draws or apheresis procedures and can be
induced to divide robustly ex vivo, a characteristic that allows
them to be highly permissible to retroviral introduction of ectopic
genes (12). The first clinical trial to safely infuse a foreign
gene into humans consisted of transducing tumor-infiltrating
lymphocytes with a neomycin resistant gene that enabled for
the detection of the transgene within a tumor biopsy sev-
eral days following transfer (13). Today, the adoptive trans-
fer of tumor-infiltrating lymphocytes combined with total-body
irradiation, lymphodepleting chemotherapy, and high-dose IL-2
achieve response rates as high as 70% in patients with metasta-
tic melanoma (14). The rapid development of gene therapy
in this field promises to vastly improve current cellular ther-
apies and opens the door to treat cancers of various histolo-
gies and wider arrays of human disease. Here, I discuss poten-
tial therapeutic genes that may improve current gene therapies,
although rigorous pre-clinical testing and careful phase 1 clin-
ical trials will be required for many of the suggestions in this
review.
CYTOKINES, CHEMOKINES, AND THEIR RECEPTORS
The theory of immune surveillance in cancer is controversial but
there exists reproducible scientific data pointing to the importance
of interferon-gamma as a critical mediator for the elimination of
malignantly transformed cells (15). Furthermore, there is a clear
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increase in the incidence of cancer in patients with HIV, Immun-
odeficiency syndromes triggered by mutations in genes such
as GATA-2 (MonoMAC) and post-transplant patients receiving
immune-suppressive drugs (16, 17).
Additional support for the importance of an immune response
for cancer elimination can be garnered from clinical data with
robust long-term follow up showing the ability of systemic IL-2,
anti-CTLA-4 antibodies, and anti-PD-1/anti-PD-L1 antibodies,
and the adoptive transfer of T lymphocytes to induce tumor
regression in patients with metastatic melanoma and metastatic
renal cell carcinoma (18, 19). Three major factors are impor-
tant for an effective immune response against cancer: (1) over-
coming suppressive factors induced by mutated cancer cells
within the tumor microenvironment, (2) the quality of the T
cells transferred, and (3) polymorphic factors of an individual’s
host immune response. Some of these factors can be readily
modified by over-expressing cytokines, chemokines, and their
receptors in transferred T cells, enabling lymphocytes to secrete
supra-physiologic amounts of therapeutic immune-stimulatory
molecules.
THE IL-12/IFN-γ/TH-1 AXIS
IL-12 is a hallmark inflammatory cytokine and is critical for
driving an effective immunologic response against cancer and
foreign pathogens (20). It is mainly produced by inflamma-
tory cells such as dendritic cells, macrophages, and neutrophils
and directly augments the functionality of multiple end effec-
tors such as CD4+ T cells, CD8+ T cells, natural killer (NK)
cells, and NKT cells (20). The anti-tumor effects of IL-12 are
well documented (21). IL-12 enhances the ability of CD8+ T
cells to cause the regression of large established tumors by
potently stimulating the production of high-levels of IFN-γ,
resulting in an increase in the cross-presentation of tumor-
antigens and the reversal of suppressive functions of myeloid-
derived suppressor cells, alternatively activated macrophages, and
dendritic cells (22). These changes subsequently lead to the col-
lapse of the tumor stroma and the regression of large established
masses (22, 23).
Unlike activated lymph nodes stimulated by pathogen-
activated molecular patterns, sterile conditions within tumors
lead to low levels of IL-12 secretion by innate immune cells.
This lack of a danger signal within the tumor microenviron-
ment results in a skewing away from a Th-1 type effector
immune response. One attractive approach is to increase the
levels of IL-12 directly at the point of T-cell/Tumor cell and T-
cell/Antigen-presenting contact within tumors (24) (Figure 1).
Several studies show that over-expressing a single-chain, func-
tionally active IL-12 gene in tumor-antigen-specific lymphocytes
significantly increases the levels of IL-12 to supra-physiological
levels within tumors, leading to the regression of large estab-
lished masses (25–28). This modification enables for therapeu-
tic anti-tumor immunity with smaller numbers of T cells and
does not require the use of systemic gamma-chain cytokines
to support the transfer of cells in vivo. Currently, clinical trials
are determining if the benefits of IL-12 gene therapy outweigh
the many risks associated with a systemic increase in IL-12 and
IFN-γ.
FIGURE 1 | Potential therapeutic gene therapies inT cells for Cancer
and Infectious Diseases.
ADDITIONAL CYTOKINES, CHEMOKINES, AND CHEMOKINE RECEPTORS
The importance of gamma-chain cytokines in the prolifera-
tion and maintenance of memory T cells remains a critical and
extremely important avenue of research for many investigators
(29–32). However, clinical trials using TIL transduced with the
IL-2 gene did not show a clinical benefit (33). Over-expressing
the other gamma-chain cytokines such as IL-7, IL-15, or IL-21
in T cells may lead to better results. However, the constitutive
expression of genes that drive T-cell proliferation carries the risk
of causing an uncontrollable expansion of transferred T cells due
to the stable integration of retrovirally transduced genes being
expressed in every daughter cell (Figure 1). Designing viral vec-
tors using a NFAT promoter for inducible gene expression upon
T-cell receptor (TCR) ligation may provide an important degree of
safety (26). Another strategy is to use adenoviral vectors or systems
that only transiently express the genes that control T-cell memory
formation.
Other potentially attractive cytokines include those within the
IL-12 family, such as IL-23, and IL-27 (Figure 1). These cytokines
may invoke beneficial downstream mechanisms for anti-tumor
immunity without the heavy reliance on the induction of IFN-γ
secretion. Furthermore, genetic polymorphisms within the human
population may make certain individuals more likely to mount an
anti-tumor response to one of the alternate members of the IL-12
family rather than IL-12 itself.
Another strategy that may turn out to be fruitful is the over-
expression of chemokines and chemokine receptors in T cells
(Figure 1). Melanomas can secrete chemokines such as CXCL1 and
CXCL8 to aid in the recruitment of monocytes into local microen-
vironments and studies show that expressing the chemokine recep-
tor CXCR2 on transferred T cells aids in the ability of T cells
to infiltrate tumors and cause regression (34). This approach
can be easily tailored to other tumor histologies depending on
the chemokine secretion profile of the cancer. Additionally, over-
expressing chemokines in T cells may also provide some benefit.
Upon recognizing cognate antigens, T cells arrest their migra-
tion and accumulate at sites with productive antigen presentation.
The over-expression of chemokines such as IP-10 or CCL5 in
transferred T cells may enable antigen-specific T cells to secrete
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products that attract activated T cells to the local microenviron-
ment they inhabit. This in turn may provide a positive feedback
loop that enables for an increase in infiltrating antigen-specific T
cells and an improved therapeutic outcome. Thus, the possibility
to genetically alter the cytokine or chemokine profile of adoptively
transferred T cells may prove to enhance and simplify current
treatments requiring lymphodepletion and high-dose IL-2.
CHIMERIC-ANTIGEN RECEPTORS
The ability to generate a single fusion molecule that can bind
surface antigens and trigger T-cell function holds great promise
for the future of cell therapy. Chimeric-antigen receptors (CAR)
are the latest form of gene therapy, where a single vector is con-
structed with a binding moiety recognizing a surface antigen
[usually designed from a single-chain variable fragment (scFv)
derived from a tumor-antigen-specific monoclonal antibody] (35–
37). The beauty of CAR generated T cells is the ability to generate
lymphocyte specificity in an MHC-independent fashion due to
the ability to design receptors that recognize surface antigens.
This is accomplished by cloning the sequences from the vari-
able region of antibodies (many of which already exist) and
adding T-cell signaling and co-stimulatory domains to the vector
construct.
Early phase trials for CARs recognizing the antigen CD19,
expressed on many B cell lymphomas and leukemias are show-
ing promising results in adult and pediatric patients at multiple
institutions (38–41). One of the major advantages of using CARs
as the main platform for gene therapy is the ability to rapidly
and clearly define the expression of the target protein. Often, the
antibodies whose variable region is cloned into the CAR vector
can also be used diagnostically to look for the expression of the
desired target.
Other antigen targets that may be worthwhile exploring for
CAR development includes GD-2 for neuroblastomas (42), CD20
(43), and CD22 for B cell lymphomas (44), BCMA (B cell matu-
ration antigen) (45), and CD38 for multiple myeloma (46), CD23
for chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) (47), CD30 for Hodgkin’s lymphoma and anaplastic
large cell lymphomas (48), CD33 for acute myeloid leukemias (49),
EGFRvIII for glioblastomas (50) and PSCA (51) and PSMA (52)
for prostate adenocarcinomas (Figure 1).
T-CELL RECEPTORS
Although CAR-directed gene therapy remains a promising modal-
ity for the future, many cancers, especially carcinomas and sarco-
mas, do not possess known surface expression of unique non-
shared antigens. Targeting surface proteins that may be expressed
on normal tissue with CARs may cause serious end organ dam-
age and toxicity. Gene therapy using high avidity TCR enables
for the design of lymphocytes targeting epitopes from differen-
tially expressed or mutated intra-nuclear and/or intra-cytoplasmic
proteins such as transcription factors (22, 53). Emerging data
now shows that tumor-infiltrating lymphocytes possess the ability
to recognize mutated melanoma antigens (54, 55). This excit-
ing finding opens up a large window of opportunity to develop
effective TCR gene therapies. It is possible that in the future
we may perform whole exome sequencing for every tumor for
diagnostic purposes, enabling us to design TCR recognizing the
most frequently mutated epitopes for different tumor histologies.
A great example of the success of TCR gene therapy was recently
described with a clinical trial utilizing the NY-ESO TCR (56). This
study led to significant tumor regression in four out of six patients
with synovial sarcoma and five out of 11 patients with metastatic
melanoma. Overall, the cancer-testis antigens represent an ideal set
of target antigens due to their relatively low to negligible expres-
sion on normal tissue, except in the testis, where cells express low
levels of MHC Class I. Identifying antigens with limited normal
tissue distribution will be critical to extending TCR gene therapy
to different types of cancer. Developing TCRs for breast, prostate,
and thyroid cancer also seems reasonable since targeting of nor-
mal tissue in these organs might not be accompanied with serious
life-threatening adverse events (Figure 1).
CO-STIMULATORY MOLECULES
Generating both a specific and a productive T-cell response
requires not only appropriate signaling through the TCR but an
additional secondary co-stimulatory signal. The most well studied
co-stimulatory molecule is CD28, a disulfide linked homodimer
that is constitutively expressed on naive T cells (57). CD28 engage-
ment with CD80 and CD86 on antigen-presenting cells enables T
cells to differentiate and become functionally activated (57). How-
ever, after initial antigen encounter and under altered cytokine
conditions, T cells can lose or decrease their expression of CD28,
leading to replicative senescence and functional anergy. The lack of
CD28 signaling can also result in an impaired memory response
and activation induced cell death (AICD) (58). One strategy to
circumvent these physiological restraints is to constitutively over-
express CD28 in T cells. Currently, second and third generation
CAR constructs use the intracellular domain of CD28 to improve
the persistence, function, and activity of CAR transduced T cells
(59). Other important co-stimulatory molecules include 41BB,
CD27, OX40, CD40, CD27, ICOS, Fas ligand, and the Slam fam-
ily of proteins (60, 61). These molecules all have been implicated
in tipping the balance in favor of generating a functional T-cell
response and helping avoid AICD during antigen re-stimulation.
The intracellular domains of 41BB, OX40, and CD27 are currently
being incorporated into various CAR constructs that are being
developed. Thus, it is possible that the constitutive over-expression
of these various co-stimulatory molecules may aid in designing
long lived, functionally active T cells that are resistant to cellular
senescence (Figure 1).
SEVERE COMBINED IMMUNODEFICIENCY SYNDROMES
The first successful therapeutic gene therapy in humans in the
early 1990s involved treating two children with severe combined
immunodeficiency syndrome (SCID) caused by a genetic defect
in the enzyme adenosine deaminase (SCID-ADA) (62). This syn-
drome resulted in defective T and B cells, leading to debilitat-
ing recurrent opportunistic infections. A normal/wild type ADA
gene, enabling for the production of a functional enzyme, was
introduced into T cells and infused back into the patient. The
results were striking, and for the first time in these patients, there
was evidence for IgM antibody production and the detection of
tetanus antibody in the serum following immunization (62). In
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one patient, approximately 20% of the circulating lymphocytes
still expressed the retrovirally inserted gene 10 years following
transfer (63).
Although these initial results led to heightened optimism,
attempts to develop gene therapies for SCID-X1, a disease char-
acterized by a defective common gamma-c cytokine receptor
subunit, by retroviral transfer of the corrected gene into CD34+
hematopoietic stem cells, led to the development of leukemias in
some patients (64, 65). These setbacks sent shock waves through
the scientific and medical communities. We now know that retro-
viral vectors can result in insertional mutagenesis, although this
phenomenon still remains poorly understood (66). Five out of 20
patients treated in trials carried out in London and Paris developed
leukemias secondary to the expansion of clones containing vector
integration near proto-oncogenes such as CCND and LMO2 (65).
Despite the clear dangers of gamma-retroviral gene transfer
into hematopoietic stem cells, transferring genes into T cells ex
vivo appears to be much more resistant to oncogenic transfor-
mation. There now exists robust long-term follow up for over
a 100 patients treated on various gene therapy trials utilizing ex
vivo retroviral insertion of genes into T cells with no evidence of
malignant transformation (9). The mechanisms for the differences
in oncogenesis between transducing hematopoietic stem cells ver-
sus T cells is not well understood. Perhaps introducing genes into
more differentiated cells that contain a vastly different genetic and
epigenetic landscape from stem cells leads to retroviral integration
away from oncogenes.
Currently, gene therapists are continuing to try to improve
safety through vector design. One strategy gaining support
includes creating self inactivating gamma (SIN) retroviral vectors
and lentiviral vectors by deleting the U3 region in the 3′ LTR (67).
This modification generates a pro-virus with defective transcrip-
tional activity at both the 5′ and 3′ LTR end regions, preventing the
possibility of transcriptionally activating cellular oncogenes near
the site of viral integration. Importantly, an internal promoter will
need to be designed to drive the expression of the desired trans-
gene within the SIN vector construct. Additionally safety measures
include the genetic modification of shorter lived cell populations
or the use of suicide genes (68).
The current progress in improving the safety of gene therapies is
helping the field move forward. In regard to SCID, although muta-
tions in the common gamma-c chain receptor is the most common
cause of the disease, a broad range of single-gene mutations can
result in a similar disease pattern of recurrent opportunistic infec-
tions (Figure 2). Theoretically, for all the various defects that may
occur, introducing a correctly functioning gene ex vivo into T cells
or hematopoietic stem cells/monocyte/dendritic cell populations
may re-capitulate the early excitement seen in the SCID-ADA trials
and build on the recent successes of gene therapy for cancer.
AUTOIMMUNE AND INFLAMMATORY DISEASES
Although genetic modifications to stimulate the immune sys-
tem is beneficial for battling infectious organisms and cancer,
there also exists a set of devastating diseases that are caused by
an over-zealous and unchecked immune response. The targeting
of self-antigens under normal physiologic conditions can cause
a range of serious ailments including type 1 diabetes, multiple
FIGURE 2 | Potential therapeutic genes to over-express in
hematopoietic stem cells, monocytes, dendritic cells orT cells for
autoimmune, inflammatory, and single-gene disorders.
sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and
autoimmune encephalomyelitis. Recently, a relatively new set of
autoimmune diseases categorized as autoinflammatory diseases
are beginning to be characterized such as familial Mediterranean
fever (FMF), neonatal onset multisystem inflammatory disease
(NOMID), tumor necrosis factor (TNF) receptor-associated peri-
odic syndrome (TRAPS), deficiency of the Interleukin-1 recep-
tor antagonist (DIRA) and Behcet’s disease (69, 70). Additional
inflammatory diseases that cause morbidity and mortality in a
large number of patients include inflammatory bowel disease
(Crohn’s disease and ulcerative colitis), chronic granulomatous
disease (CGD), and the various forms of vasculitis (71, 72).
In general, dampening the immune response is the ideal treat-
ment for autoimmune and inflammatory diseases and current
therapies revolve around the use of steroids, cytokine antago-
nists, or directly down regulating the immune system utilizing
various modalities. Gene therapies may provide a viable biolog-
ical alterative to directly blunt an over-active immune response.
Over-expressing anti-inflammatory cytokines such as IL-10, TGF-
β, IL-30, IL-35, or IL-37 in T cells or monocyte/dendritic cell
populations ex vivo with a re-infusion of the modified cells may
aid in decreasing inflammatory driven symptoms (Figure 2).
Another alternative may be to construct a decoy cytokine receptor
that contains the correct receptor sequence to enable for binding
of pro-inflammatory cytokines such as IL-12 combined with a
non-functioning cytoplasmic signal transducing sequence. Over-
expressing these “dominant-negative” receptors would enable re-
infused immune cells to function as sinks for the inflammatory
cytokines responsible for the pathophysiology of the disease.
Other genes that may aid in dampening the immune response
include over-expressing indoleamine 2,3-dioxygenase in mono-
cytes/dendritic cells or CTLA-4, PD-1, CD95, LAG-3, FOXP3, and
BACH2 in T cells (73) (Figure 2).
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SINGLE-GENE DEFECTS
Although many human diseases are caused by complex genetic
polymorphisms, perhaps the greatest potential for gene therapy
is in the ability to treat diseases caused by single Mendelian
gene defects. Mutations in genes such as IFNGR1, STAT1, IL-
12, and IL-12R can lead to immune dysfunction and recur-
rent mycobacterial infections (74). Genetic disruptions also
cause many of the autoinflammatory diseases, such as muta-
tions in the FMF gene in FMF, the LNRP3 gene in NOMID,
the TNFR gene in TRAPs, and IL1RN gene in DIRA. Insert-
ing the corrected sequence for these genes into hematopoi-
etic cells or more safely into differentiated immune cells may
result in dramatic improvements in the health of these patients
(Figure 2).
CONCLUSION
T lymphocytes represent one of the first vehicles to carry ther-
apeutic genes into humans, and its current use, centered on the
adoptive transfer of T cells, is proving to be a promising can-
cer therapeutic modality. However, logistic hurdles still exist for
the wider use of this technology due to costs associated with
GMP quality viral production and the requirement of significant
technologic infrastructure and expertise. Increased collaboration
between industry and academia for developing gene therapies may
help overcome current financial limitations by developing viable
business models.
There exist over 4000 known single-gene disease causing dis-
orders in addition to the innumerable genetic polymorphisms
that increase susceptibilities for diseases. Gene therapy in T cells
is paving the way for a broader application of this therapeutic
modality in human disease. The ability to stably introduce func-
tional genes into hematopoietic stem cells or differentiated cells ex
vivo provides hope for the thousands of patients diagnosed with
a wide range of devastating genetic diseases, highlighted by recent
successes in childhood cerebral adrenoleukodystrophy (75) and
hemophilia B (76). Gene therapy represents the ultimate form of
personalized medicine, and in the future, it is conceivable to imag-
ine that diseases that were once considered untreatable will be
readily controlled or eradicated with a single specialized treatment.
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